We have designed a set of oligonucleotide primers to amplify the cDNA of mouse immunoglobulin heavy and light chain variable domains by the polymerase chain reaction. The primers incorporate restriction sites that allow the cDNA of the variable domains to be force-cloned for sequencing and expression. Here we have applied the technique to clone and sequence the variable domains of five hybridoma antibodies and to express a mouse-human chimeric antibody that binds to the human mammary carcinoma line MCF-7. The technique should also lead to the cloning of antigen-binding specificities directly from immunoglobulin genes.
For serotherapy, human monoclonal antibodies (mAbs) would be preferred to mouse mAbs because the foreign immunoglobulin can elicit an anti-globulin response that may interfere with the therapy (1) or cause allergic or immune complex hypersensitivity (2) . However, there are considerable difficulties in making human mAbs of the required specificity by hybridoma technology (3) . Recently, protein engineering has been used to convert mouse mAbs into "human" mAbs by joining the entire immunoglobulin variable (V) domains from mouse mAbs to human constant (C) domains (4) (5) (6) or by transplanting the complementaritydetermining regions (CDRs) of the mouse mAbs into human myeloma proteins (7) (8) (9) . Thus, the rearranged immunoglobulin V genes provide the raw material for engineering and have been derived by cloning from genomic DNA (10, 11) or cDNA (12) .
The polymerase chain reaction (PCR) (13) has been used recently for genomic (14) and cDNA cloning (15) . It involves repeated rounds of extension from two primers specific for regions at each end of the gene. The primers need not match the gene sequence exactly (16) , and restriction sites can be incorporated within the primers to allow the forced cloning of the amplified DNA (14) . In principle, the restriction sites within the PCR primers could be devised to clone a gene directly for expression, although this has not been described. Therefore, we sought to apply the PCR to the cloning and expression of immunoglobulin V genes.
First, we identified conserved regions at each end of the nucleotide sequences encoding V domains of mouse immunoglobulin heavy chain (VH) and K light chain (VK). Second, we designed primers for the amplification, which incorporated restriction sites for forced cloning. Third, we constructed vectors that allow the amplified cDNA to be expressed, while retaining the amino acid sequence typical of V domains. We then applied the technique to clone and sequence cDNA encoding five mouse mAbs of therapeutic potential: MBrl (17) , BW 431/26 (18) , BW 494/32 (19) , BW 250/183 (18, 20) , and BW 704/152. MBr1 has been raised against a human mammary carcinoma line MCF-7 and recognizes a saccharide epitope (21) . The cDNA of the MBrl VH and VK domains (mouse g and K chains) was expressed as a simple chimeric antibody (human 'yl and K chains). The human yl isotype was chosen, as it should mediate cell killing by both complement lysis and cell-mediated routes (9, 22) .
METHODS
Comparison of Nucleotide Sequences. The aligned entries of the nucleotide sequences of the V genes were extracted from the Kabat data base (23) : the beginning of the nucleotide sequences correspond to the mature N terminus of the protein, and nucleotides encoding the protein signal sequences are not included. To allow manipulation of the data with the computer program DBUTIL (24) and analysis with the FAMNS and PLOTD programs (R. Staden, personal communication), the entries were entered into a shotgun sequencing data base (24) . By using DBUTIL, each VH or VK block was trimmed to a "core alignment" by removing positions encoding extra amino acid residues (A to K in ref. 23 ) except for residues 82A, 82B, and 82C of the VH domains. By using FAMNS, the frequency of the most common nucleotide was scored for each site, and the information was used to design the amplification primers (see Results). By using PLOTD, the 14 nucleotides at the 3' end of the forward and back primers (see below) were matched with each entry in the data base. (Entries with nucleotides missing in this section of sequence were excluded from the comparison.) Likewise, PLOTD was used to match up the nucleotide sequences encoding CDR1 and CDR2 of MBrl VH and VK domains with each of the entries in the data base.
cDNA Synthesis and Amplification. RNA was prepared from about 5 x 101 hybridoma cells grown in roller bottles, and mRNA was selected on oligo(dT)-cellulose (25 Vector Construction. To make the phage M13-VHPCR1 vector, a BstEII site was introduced into the M13-HuVHNP vector (7) by site-directed mutagenesis (27, 28 (31) by electroporation (32) . Cells were selected in the presence of mycophenolic acid at 0.3 ttg/ml after 1 day and at 1 ,ug/ml after 7 days. After 14 days, four wells, each containing one or two major colonies, were screened by incorporation of ['4C]lysine (33) , and the secreted antibody was detected after precipitation with protein A-Sepharose (Pharmacia) on NaDodSO4/PAGE (34) . The gels were stained, fixed, soaked in fluorographic reagent Amplify (Amersham), dried, and autoradiographed on preflashed film at -70'C for 2 days. Supernatant was also tested for binding to the mammary carcinoma line MCF-7 and the colon carcinoma line HT-29 essentially as described (17) in Methods. The frequency of the most common nucleotide was plotted for each position in the aligned VH and VK gene domains (Fig. 1) . As expected, the nucleotide sequences encoding the protein CDRs are variable, and those corresponding to the joining (J)-region segments are conserved. However, there are several other conserved regions, in particular those encoding the mature N terminus of both VH and VK domains.
Amplification primers VH1FOR and VK1FOR were designed to be complementary to the mRNA in the J regions; and primers VH1BACK and VK1BACK, to be complementary to the first-strand cDNA encoding the conserved Nterminal region. VH1BACK primer has a mixed sequence. The restriction sites for forced cloning were incorporated toward the 5' end (the least conserved part) ofthe primer, and mismatches were minimized near the 3' end.
The degree of complementarity of the 3' end of each primer to each ofthe entries in the Kabat data base was checked with PLOTD. For most entries, this region of the primer proved to be perfectly matched or with only one or two mismatches ( Table 1) . The 3' ends of the forward primers were also checked against each of the mouse heavy and light chain J regions, and the 3' ends of the back primers with consensus sequences derived from each ofthe mouse VH and VK families (as listed in ref. 23 ). The pnmers match well to each J region or mouse V gene family, apart from the VK1BACK primer, which has several mismatches with the mouse VK II family.
The scheme for cloning of VH and V,, sequences from mouse Ig mRNA is shown in Fig. 2 (17) (18) (19) (20) by using the amplification primers. A typical result is shown in Fig. 3 , in which the amplified cDNA gives a major band of the expected size (about 320-350 bp), although its intensity varies and there are also smaller bands. For the V, cDNA of MBr1, the band was very weak and was excised from the gel and reamplified in a second round (not shown). After digestion with restriction enzymes, the cDNA was gel-purified and cloned into the M13-VHPCR1 and M13-VKPCR1 vectors. The clones containing VH or VK gene inserts were identified directly by sequencing, as the majority carried correct inserts. (There is an internal Pst I site in the VH gene of BW 431/26, and the gene was therefore assembled in two steps: the 3' Pst IBstEII fragment was first cloned into M13-VHPCR1, followed in a second step by the 5' Pst I fragment.)
A comparison of the sequences of VH and VK domains from the five antibodies with the Kabat protein data base (23) revealed that there were five different mouse VH families (IA, TB, 11A, IIB and IIIA) and two different mouse VK families (I and VI) ( Table 2) . To ensure accuracy, the sequences ofthe V genes for each antibody were determined from two independent amplifications from the cDNA-mRNA hybrid or, in the case of MBr1, from two independent batches of mRNA. With the exception oftwo single nucleotide discrepancies and a deletion of three nucleotides beyond the 3' end of the VK1BACK primer (presumably due to slippage of the Fig. 4 with part of the flanking regions of the M13-VHPCR1 and M13-VKPCR1 vectors. There are some unusual features of the MBr1 sequence-for example, CDR3 of the VH domain is very short (35) , with a diversity (D) segment encoding apparently only three amino acids. However, these features proved identical in two independent clones. The nucleotide sequences of CDR1 and CDR2 of MBr1 V genes were screened against each of the entries in the Kabat data base using PLOTD. This showed that the sequence of the MBr1 VH gene was most closely related to that of 119.1, a member ofthe 4-hydroxy-3-nitrophenylacetyl (NP) major idiotypic family (36) . secreted antibody (Fig. 5) . The chimeric antibody in the supernatant, like the parent mouse MBr1 antibody, was found to bind to the mammary carcinoma MCF-7 but not to the colon carcinoma HT-29.
DISCUSSION
The sequencing and cloning of immunoglobulin V genes is the first and often rate-limiting step in making simple chimeric or reshaped human antibodies. We have devised a simple and rapid way of cloning these genes via the PCR. By making a systematic comparison ofthe aligned sequences ofVH and VK genes, we have identified nucleotide sequences at the 5' ends of both VH and V,, genes that are relatively conserved. Since the JH and J,, regions at the 3' ends of the genes are also conserved, we were able to design primers for PCR amplification based on these sequences and to include restriction sites for forced cloning. In general, the clones could be screened directly by sequencing, with almost all of the recombinants carrying the correct inserts.
From (38) . As alternative to sequencing independent clones, the amplified cDNA could be sequenced directly (37).
Proc. Natl. Acad. Sci. USA 86 (1989) 3837 Given our choice of priming sites, it is not possible to determine the exact sequence at both ends of the V genes, as it is dictated by the primer. However, to some extent, we can reconstruct the sequence in these regions (Fig. 4) 
